Neurocrine Biosciences (NASDAQ:NBIX) released its quarterly earnings data on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.11), Bloomberg Earnings reports. The firm had revenue of $94.52 million for the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the prior year, the firm posted ($0.51) EPS.
Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $85.38 on Thursday. Neurocrine Biosciences has a 1 year low of $39.21 and a 1 year high of $91.82. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 3,750 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $78.89, for a total transaction of $295,837.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Darin Lippoldt sold 6,279 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $75.04, for a total transaction of $471,176.16. Following the transaction, the insider now owns 19,436 shares in the company, valued at approximately $1,458,477.44. The disclosure for this sale can be found here. Insiders sold 337,950 shares of company stock worth $26,613,876 in the last 90 days. 4.80% of the stock is currently owned by company insiders.
Several research firms have recently issued reports on NBIX. Oppenheimer set a $100.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday. Deutsche Bank lifted their price objective on shares of Neurocrine Biosciences to $97.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays reiterated an “overweight” rating and set a $100.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, BidaskClub upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Neurocrine Biosciences has a consensus rating of “Buy” and an average target price of $89.53.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.